IP
SGMO

Intellectus Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Intellectus Partners’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,500
Closed -$25K – 465
2018
Q3 		$25K Buy
+1,500
New +$22.8K 0.01% 413

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Intellectus Partners's SGMO Position: Q4 2018 in Review

Intellectus Partners sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2018, closing a stake of 1,500 shares — an estimated $25K sold.

Intellectus Partners first reported a position in SGMO in Q3 2018 and held it in 1 quarter. The position peaked at $25K in Q3 2018. 197 funds tracked by Wall St. Rank hold SGMO as of Q4 2018.

  • Intellectus Partners reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 1,500 SANGAMO THERAPEUTICS INC shares in Q4 2018, an estimated $25K.
  • Intellectus Partners first reported a position in SANGAMO THERAPEUTICS INC in Q3 2018 and held it in 1 quarter.
  • Intellectus Partners's SANGAMO THERAPEUTICS INC position peaked at $25K in Q3 2018.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.